On patient reported outcomes in adoptive cell therapy.

"Interestingly, only 6.8 % of the recently published CAR-T trials investigated PROs as a primary or secondary outcome measure,6 and none of the TIL-ACT clinical trials in solid tumors included PROs as corollary endpoints. Indeed, much of academia’s and industry’s efforts to date have been aimed at shifting the cost-effectiveness balance of these therapies by understanding biological features of efficacy (cancer target identification, T-cell product characteristics, biomarkers of response, etc), improving the manufacturing pipeline, and scalability. Surprisingly, limited efforts have been directed to understand patients’ perspectives during cell-therapy trials."

#AdoptiveCellTherapy #PatientReportedOutcomes #immunotherapy #ClinicalTrials #DrugDevelopment

https://jitc.bmj.com/content/10/12/e006082

Referenced link: https://cassyni.com/events/HdEFL124gpxCK6nLvVCevq
Discuss on https://discu.eu/q/https://cassyni.com/events/HdEFL124gpxCK6nLvVCevq

Originally posted by Nature Portfolio / @NaturePortfolio@twitter.com: https://twitter.com/SN_Oncology/status/1597893457271730177#m

RT by @NaturePortfolio: Join our Springer Nature Oncology webinar on ‘Natural Killer Cell Therapy’ today, or sign up to view the recording later if you are unable to attend the live event:
https://cassyni.com/events/HdEFL124gpxCK6nLvVCevq
#NKCellTherapy #NKCell #AdoptiveCellTherapy #CARTcelltherapy #cancerimmunotherapy